EIF4E program (Cloud Pharmaceuticals/Egenix)

N/A

Report date: 2025/03/20 15:04:08
NME

Base Information

Drug NameEIF4E program (Cloud Pharmaceuticals/Egenix)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEukaryotic translation initiation factor 4E modulators
TargetsEukaryotic translation initiation factor 4E
Therapy Area/IndicationsAutistic DisorderNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCloud Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesCloud Pharmaceuticals Inc
Inactive CompaniesEgenix Inc
Active IndicationsAutistic DisorderNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A